Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZZ1001
- Development stage
- Preclinical
- Lead developer
- Zhongze Therapeutics
- Modality
- Small Molecules
01
Overview
ZZ1001 (also known as ZZ-1001) is a discovery-stage small molecule drug candidate being developed by Zhongze Therapeutics (Zhongze Therapeutics Hong Kong Ltd.) for the treatment of schizophrenia. It is designed to act as a multi-target modulator, specifically targeting serotonin (5-HT) receptors and dopamine D5 receptors. The compound is part of Zhongze's pipeline of innovative central nervous system (CNS) therapies, which includes other candidates like ZZ6398 (SIPI6398) and ZZ2101. ZZ1001 aims to address the complex pathophysiology of schizophrenia by modulating neurotransmitter pathways associated with the disease's positive, negative, and cognitive symptoms.
02
Targets
DRD5 (Dopamine D5 Receptor)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on ZZ1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZZ1001.